ArticleBritish journal of cancer2013

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.

P Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.